Yuhan Corp. (000100) fair value: what the stock is really worth
As of Nov 19, 2026: fair value (intrinsic value) of Yuhan Corp. stock KRW 28,619, price KRW 81,300, that is 64.8% below the price, quality 55 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Yuhan Corp.
000100 · KOFar too expensive (fair value 65% below the price) and falling price, but solid company: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 20, 2026.
How to read this chart
60‑month range 46,936 KRW – 162,125 KRW · fair‑value band 26,604 KRW – 33,636 KRW · the 81,300 KRW price screens above the 28,619 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 20, 2026.
Every Wednesday you see whether Yuhan is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally.
Show moreShow less
It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and analytical method development and regulatory support.
The company also provides APIs and intermediates, including antibiotic, anti-thrombotic, anti-hyperlipidemics, and anti-hypertensive; and custom synthesis services through commercial supply in areas of anti-viral, anti-HIV, anti-HCV, anti-biotic, antihistamine, anti-diabetic, ß-lactamase inhibitor, CNS intermediate, PEG-compounds, and others.
Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.
Stock analysis
Yuhan Corp. (000100) currently trades at 81,300 KRW, while our model-based Fair Value estimate is 28,619 KRW, 65% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 52,638 KRW per share, and 1 of the 16 models we run sit above the 81,300 KRW price.
Bear case: the Asset-Based group reads lowest at 8,117 KRW, and 15 of the 16 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 26,604 KRW (bear) to 33,636 KRW (bull), the price of 81,300 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Yuhan Corp. reported revenue of 2.2T KRW in FY2025 versus 1.7T KRW in FY2021, a compound +6.7%/yr. Reported net income was 194B KRW in FY2025, compounding +17.3%/yr from FY2021.
Key figures
Market cap 6.0T KRW (≈ $4.5B) Mid · P/E ratio 25.6 · P/S ratio 2.62 · EPS (TTM) 3,131 KRW · Dividend yield 0.7% · Net margin 10.4% · Return on equity 9.5% · Return on assets (EBIT) 2.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
Analysts expect earnings well below the last reported figure (earnings in transition, for example expiring patents or contracts); a fair value that looks fair on trailing earnings may then be too optimistic.
The share trades about 33% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −65%, 000100 screens richer than that median.
Fair Value models
All 16 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
000100 screens overvalued: fair value 65% below the price. Compare with Merck KGaA →
Compare Yuhan Corp. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Dividend yield by industry
- EV/EBITDA by industry
- PEG screener for stocks with fair value
- Undervalued stocks: South Korean Stocks
- Valuation of the Korea market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $80.79 | $113.53 | +41% | vs 000100 |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥46.88 | ¥52.43 | +12% | vs 000100 |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,900 | ₹1,983 | +4% | vs 000100 |
| Haleon plc HLN | $9.05 | $8.47 | −6% | vs 000100 |
| Merck KGaA MRK | €148.40 | €108.83 | −27% | vs 000100 |
| Galderma Group GALD | CHF 184.70 | CHF 112.46 | −39% | vs 000100 |
| Teva Pharmaceutical Industries Limited TEVA | $38.54 | $20.74 | −46% | vs 000100 |
| Takeda Pharmaceutical Company TAK | $21.41 | $11.23 | −48% | vs 000100 |
| Sandoz Group SDZ | CHF 81.24 | CHF 41.06 | −49% | vs 000100 |
| Divi's Laboratories Limited DIVISLAB | ₹11,178 | ₹1,567 | −86% | vs 000100 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Yuhan Corp. (000100) overvalued or undervalued?
What is the fair value of 000100?
What is the quality score of 000100?
What is the price target for Yuhan Corp. (000100)?
What is the Yuhan Corp. stock forecast for 2026?
What is the revenue of Yuhan Corp. (000100)?
Does Yuhan Corp. pay a dividend?
How much is the dividend of Yuhan Corp. (000100) and when is the ex-dividend date?
What is the intrinsic value of Yuhan Corp. (000100)?
Is Yuhan Corp. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 000100?
How much is Yuhan Corp. worth?
What do the bullish and bearish scenarios say about 000100?
What is the P/E ratio of 000100?
How solid is the balance sheet of Yuhan Corp. (000100)?
How far is 000100 from its 52-week high?
Which stocks are comparable to Yuhan Corp.?
Is Yuhan Corp. stock attractive at the current price?
How is the fair value of 000100 calculated?
Is it still worth investing in stocks now?
What is the share price of Yuhan Corp. (000100)?
What should I pay attention to with Yuhan Corp. right now?
Key figures of Yuhan Corp.
How large is the market capitalisation of Yuhan Corp. (000100)?
What is the P/S ratio of Yuhan Corp. (000100)?
What are the earnings per share of Yuhan Corp. (000100)?
What is the dividend yield of Yuhan Corp. (000100)?
What is the net margin of Yuhan Corp. (000100)?
What is the return on equity of Yuhan Corp. (000100)?
What is the EBIT return on assets of Yuhan Corp. (000100)?
What is the operating margin of Yuhan Corp. (000100)?
How fast is revenue growing at Yuhan Corp. (000100)?
How fast are earnings growing at Yuhan Corp. (000100)?
How much free cash flow does Yuhan Corp. (000100) generate?
Watch Yuhan Corp. in the live analysis
One click puts Yuhan Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.